Pantheon Vision Inc

Thank you, Healio for the great conversation at . We appreciate the opportunity to talk about corneal blindness, the challenges with corneal transplants and the importance of meeting the critical needs of patients around the world. .

VIDEO: Pantheon Vision shares new approach to address corneal blindness BOSTON — In this Healio Video Perspective from the ASCRS meeting, John Sheets, PhD, of Pantheon Vision previews a product designed to address unmet needs in corneal blindness compared with the standard of care of transplantation.

Thank you, Guided Solutions - Global Executive Search in Medical Devices, for sharing the news of our two pre-submission meetings with the FDA. We appreciate the coverage!

Pantheon meets with FDA to discuss PMA submission for corneal implants Pantheon meets with FDA to discuss PMA submission for corneal implants - Regulatory Approvals

BioSpace recently featured the news of our pre-submission meetings with the FDA. These early conversations provided valuable guidance on our preclinical and clinical work in support of a Pre-Market Approval (PMA) submission. Thanks for the coverage!

Pantheon Vision Announces Two Successful Pre-Submission Meetings With the FDA | BioSpace Pantheon Vision announced today the completion of two successful and productive Pre-Submission meetings with the U.S. Food and Drug Administration (FDA).

Thank you, Ophthalmology Times for sharing the news of our successful pre-submission meetings with the FDA. These critical early interactions provided valuable information as we continue our work toward a Pre-Market Approval submission.

Pantheon Vision holds two pre-submission meetings with FDA According to the company, the feedback from the interactive meetings will provide guidance for the path to a PMA submission.

We are honored to be recognized as a Social Impact Award Honoree presented by the of Baltimore. Each year, the Smart Business Dealmakers recognize exceptional companies and individuals who are shaping the landscape of business and innovation in Baltimore. "Thank you to Smart Business Dealmakers for this recognition. We are proud of the work our team is doing to develop new treatment options for corneal blindness and improve access and outcomes for the millions of people around the world needing a corneal transplant," says John Sheets, Ph.D., CEO and Co-Founder of Pantheon Vision. Congratulations to our fellow honorees!

Harbor Launch at IMET Maryland Department of Commerce Greater Baltimore Committee The City of Baltimore Development Corporation - BDC Baltimore Business Journal The City of Baltimore The Baltimore Sun, BioBuzz Biohealth Innovation, Inc..

Recognizing Baltimore's Smart Business Network Dealmaker Award Winners and 2024 Dealmakers Hall of Fame Class! - Smart Business Dealmakers Read about the Dealmakers of the Year we're honoring in Baltimore this year and check out the accomplishments of our Hall of Famers.

Pantheon Vision has joined the community at Harbor Launch at IMET- Institute of Marine and Environmental Technology in Baltimore. Harbor Launch is a startup incubator and community for science and science support companies. We are excited to establish our Baltimore headquarters amongst other companies that are solving problems in human and environmental health through the development of products and services. hashtag hashtag

Harbor Launch at IMET – A startup incubator and community “COVID-19 vaccination resistance has become a major challenge to prevent global SARS-CoV-2 transmission. Here we report that the vaccination coverage rate is inversely correlated to the mutation frequency of the full genome (R2=0.878) and spike gene (R2=0.829) of SARS-CoV-2 delta variants in 16 co...

We are pleased to announce that Pantheon Vision participated in two successful pre-submission meetings with the FDA. These meetings provided important feedback on our clinical approach to fighting corneal blindness for Pre-Market Approval (PMA) and were a critical step in our mission to develop a new solution for corneal blindness.

Pantheon Vision Announces Two Successful Pre-Submission Meetings With the FDA Pantheon Vision, a pre-clinical stage medical device company developing bioengineered corneal implants to eliminate corneal blindness, announced today

It's a wrap on ASCRS2024! Our team had a great time connecting with colleagues and experts and learning more about advances in treatments, research and technology in ophthalmology. See you next year!

was a success! We look forward to seeing you in Los Angeles, California, April 25–28 for https://bit.ly/2SOY7LZ

We are at - are you? Let's connect!

Today on the ASCRS Main Stage!

“If we want to increase global access to treatments that can restore sight for patients with corneal blindness, we need to find new solutions.” John Sheets, CEO, Pantheon Vision.

We look forward to connecting with colleagues at ASCRS 2024.

Going to Boston for ASCRS 2024? We are, and we want to connect with you!

Get excited! There are nearly two dozen symposia at the ASCRS Annual Meeting.

We are excited to announce that Pantheon Vision has secured a second tranche of $1.8 million in funding from KeraLink International, bringing the total amount raised to $4.3 million. These funds will be used to continue our research and development of bioengineered corneal implants, bringing us one step closer to reducing reliance on donated corneal tissue.
https://www.businesswire.com/news/home/20240402667748/en/Pantheon-Vision-Secures-a-Second-Tranche-of-1.8-Million-to-Advance-Bioengineered-Corneal-Implants

Pantheon Vision Secures a Second Tranche of $1.8 Million to Advance Bioengineered Corneal Implants Pantheon Vision Secures a Second Tranche of $1.8 Million to Advance Bioengineered Corneal Implants